Aurora Spine Corporation Celebrates Second Anniversary of Initial Implantation of the World’s First Bone Density Matched DEXA-C Cervical Interbody Fusion Device
20 März 2024 - 12:30PM
Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV:
ASG) (OTCQB: ASAPF), a manufacturer of innovative spinal implants
announced today that it has completed the second full year of
implantation of the world’s first patient-bone-density matched
interbody device, the cervical interbody DEXA-C.
Trent Northcutt, CEO and President at Aurora Spine said, "It's a
significant milestone for Aurora to celebrate the second
anniversary of the world’s first surgical implantations of the
DEXA-C patient-bone-density matched interbody devices. The DEXA-C
implants, a line of cervical cages for anterior cervical discectomy
with fusion (ACDF) procedures, are the first of its kind in the
world offering an implant based upon a patient's bone density. It
is also the first color-coded implant on the marketplace and will
help doctors match against the color-coding of a DEXA score.”
Dr. Sebastian Koga, Neurosurgeon at Koga Neurosurgery in
Covington, Louisiana said, "After two years and over 200 levels
with the DEXA-C cage, I could never go back to standard cages or
structural allograft. My colleagues who have implanted the device,
also feel the same. I am able to confidently offer multilevel
anterior fusions to patients who likely could not have benefitted
from other existing implants because of their bone density. The
interface between the woven lattice of the cage and the endplate
images very clearly on x-ray and CT and causes reduced artefact on
MRI."
Aurora announced in March 2023 that it had received
Institutional Review Board (IRB) approval for its new multicenter
study of its DEXA-C Cervical Interbody System, which is indicated
for anterior cervical interbody fusion procedures in skeletally
mature patients with degenerative disc disease (DDD) of the
cervical spine with accompanying radicular symptoms at one or two
contiguous levels from C2-T1.
In June 2023, Aurora announced that the first patient has been
enrolled for its multicenter study of DEXA-CTM Cervical Interbody
System. The commencement of the enrollment of patients indicates
that the company has received all necessary approvals to launch the
study, with initial plans to include data from 40 single level and
40 multiple level subjects.
Dr. Koga continued, “We are reviewing the first one hundred
patients in a retrospective clinical study now, while also
collecting prospective longitudinal data for the DEXA study.
Preliminarily, we have seen both in radiographs and surgical
exploration that patients have incipient bone fusion by 90 days
after surgery. This technology is now ripe for duplication in more
challenging areas of the spine. I continue to believe that that
progress is contingent on new biomaterials, and that such
personalized implants will revolutionize spine surgery.”
In February 2024, Aurora announced the issuance of its second
United States Patent No: 11,850,162 entitled “Body Density Scan
Result-Matched Orthopedic Implants and Methods of Use” for The
World’s First DEXA Technology™ Patient-Matched Implant
Technology.
Aurora is focused on the release of other devices utilizing the
patented DEXA Technology. Northcutt stated, “These patents will
allow us to create DEXA implants for use anywhere in the human body
where bone fixation is needed providing patients with previously
non-existing new treatment possibilities.”
About Aurora Spine
Aurora Spine is focused on bringing new solutions to the spinal
implant market through a series of innovative, minimally invasive,
regenerative spinal implant technologies. Additional information
can be accessed
at www.aurora-spine.com or www.aurorapaincare.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-Looking Statements
This news release contains forward-looking information that
involves substantial known and unknown risks and uncertainties,
most of which are beyond the control of Aurora Spine, including,
without limitation, those listed under "Risk Factors" and
"Cautionary Statement Regarding Forward-Looking Information"
in Aurora Spine's final prospectus (collectively, "forward-looking
information"). Forward-looking information in this news release
includes information concerning the proposed use and success of the
company’s products in surgical procedures. Aurora Spine cautions
investors of Aurora Spine's securities about important factors that
could cause Aurora Spine's actual results to differ materially from
those projected in any forward-looking statements included in this
news release. Any statements that express, or involve discussions
as to, expectations, beliefs, plans, objectives, assumptions or
future events or performance are not historical facts and may be
forward-looking and may involve estimates, assumptions and
uncertainties which could cause actual results or outcomes to
differ unilaterally from those expressed in such forward-looking
statements. No assurance can be given that the expectations set out
herein will prove to be correct and, accordingly, prospective
investors should not place undue reliance on these forward-looking
statements. These statements speak only as of the date of this
press release and Aurora Spine does not assume any obligation to
update or revise them to reflect new events or circumstances.
Contact:
Aurora Spine CorporationTrent NorthcuttPresident and Chief
Executive Officer(760) 424-2004
Chad ClouseChief Financial Officer(760)
424-2004www.aurora-spine.com
Aurora Spine (TSXV:ASG)
Historical Stock Chart
Von Sep 2024 bis Okt 2024
Aurora Spine (TSXV:ASG)
Historical Stock Chart
Von Okt 2023 bis Okt 2024